NCT06782594View on ClinicalTrials.gov

A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 18, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

October 31, 2025

Conditions
Postoperative Gastrointestinal Dysfunction
Interventions
DRUG

Mosapride Citrate Injection(high)

Mosapride Citrate Injection, iv, 8mg, bid, for 3 to 5 days

DRUG

Mosapride Citrate Injection(low)

Mosapride Citrate Injection, iv, 4mg, bid, for 3 to 5 days

DRUG

Placebo

Placebo, iv, bid, for 3 to 5 days

Trial Locations (2)

Unknown

RECRUITING

Shandong New Time Pharmaceutical Co., LTD, Feixian

RECRUITING

Tongji Hospital Affiliated to Tongji Medical College Hust, Wuhan

All Listed Sponsors
lead

Shandong New Time Pharmaceutical Co., LTD

INDUSTRY